Immunotherapeutic Targeting in Autoimmune Diseases (original) (raw)

A review of the current use of rituximab in autoimmune diseases

Haris Shekhani, Matthew Nitzberg, Joel Stern, Derin Keskin

International Immunopharmacology, 2009

View PDFchevron_right

B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis

Devita Cornelia

Rheumatology

View PDFchevron_right

Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells

Stamatis-Nick Liossis

Clinical Immunology, 2008

View PDFchevron_right

Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)

Howard Liebman

Annals of the Rheumatic Diseases, 2002

View PDFchevron_right

Prospects for B-cell-targeted therapy in autoimmune disease

G. Cambridge

Rheumatology, 2005

View PDFchevron_right

Rituximab therapy and autoimmune disorders: Prospects for anti-B cell therapy

Gregg Silverman

Arthritis & Rheumatism, 2003

View PDFchevron_right

B cell-targeted therapies in autoimmunity: rationale and progress

Paolo Fiorina, Mohamed H Sayegh

F1000 biology reports, 2009

View PDFchevron_right

Rituximab Therapy and Autoimmune Disease

Ram Asha

Current Immunology Reviews, 2012

View PDFchevron_right

B-cell depletion with rituximab in the treatment of autoimmune diseases

Klaus Bendtzen

Expert Opinion on Biological Therapy, 2007

View PDFchevron_right

B cells as a therapeutic target in autoimmune disease

Devita Cornelia

Arthritis Research & Therapy, 2003

View PDFchevron_right

Use of rituximab in immunological disorders

Rubina Naqvi

Immunopathologia Persa, 2016

View PDFchevron_right

Successful treatment of autoimmune and lymphoproliferative complications of patients with intrinsic B-cell immunodeficiencies with Rituximab

Christian Hennig

British Journal of Haematology, 2010

View PDFchevron_right

A novel targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases

Kader Thiam

Research Square (Research Square), 2023

View PDFchevron_right

Monitoring anti-B cell immunotherapies in autoimmune diseases: Go with the flow. A Position Paper of the Italian Society for Clinical Cell Analysis (ISCCA)

Bruno Brando

Beyond Rheumatology, 2019

View PDFchevron_right

Daratumumab in rituximab‐refractory autoimmune haemolytic anaemia

gayathri nair

British Journal of Haematology, 2021

View PDFchevron_right

Circulating Anti-PLA2R Autoantibodies to Monitor Immunological Activity in Membranous Nephropathy

Paolo Cravedi

Journal of the American Society of Nephrology, 2011

View PDFchevron_right

Current and future approaches to the treatment of immunologic diseases: new targets and new therapeutic agents

David Fox

Translational research : the journal of laboratory and clinical medicine, 2015

View PDFchevron_right

Anticytokine therapy impacting on B cells in autoimmune diseases

Capucine Daridon

Current Opinion in Rheumatology, 2009

View PDFchevron_right

Monoclonal Antibody Therapy Role in Autoimmune Diseases

ali alqattan

2018

View PDFchevron_right

The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies

Nazila Bahmaie

International Immunopharmacology, 2021

View PDFchevron_right

Rituximab and its Use in Autoimmune Bullous Disorders

Dedee Murrell

Dermatologic Clinics, 2011

View PDFchevron_right

The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease

Fausta Catapano

BMC Musculoskeletal Disorders, 2014

View PDFchevron_right

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

Ester Quintana

Frontiers in Immunology, 2021

View PDFchevron_right

Circulating (CD3−CD19+CD20−IgD−CD27highCD38high) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?

Karen Willard-Gallo

Mediators of Inflammation, 2016

View PDFchevron_right

B-Cell Targeted Therapies in Autoimmune Cytopenias and Thrombosis

Imad Uthman

Milestones in Drug Therapy, 2013

View PDFchevron_right

CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity?

Athina Pyrpasopoulou

BioMed research international, 2014

View PDFchevron_right

The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases

Giusepe Bataglia

Neurological Sciences, 2011

View PDFchevron_right

Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future

Michael Walsh

Kidney International, 2007

View PDFchevron_right

B-Cell Depletion and Repopulation in Autoimmune Diseases

Jacques-olivier Pers, Pierre Youinou

Clinical Reviews in Allergy & Immunology, 2008

View PDFchevron_right

Cellular Targeting in Autoimmunity

T Tarrant

Current Allergy and Asthma Reports, 2012

View PDFchevron_right

Circulating (CD3−CD19+CD20−IgD−CD27highCD38high) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?

Ingrid Beukinga

Mediators of Inflammation, 2016

View PDFchevron_right

Application of Monoclonal Antibody Therapies in Autoimmune Diseases

Gabriella Sarmay, József Prechl

View PDFchevron_right

Exploring the role of immunotherapeutic drugs in autoimmune diseases: A comprehensive review

Saiid Beshir

Journal of Oral Biology and Craniofacial Research, 2021

View PDFchevron_right

A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti–Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy Patients

Umberto Maggiore

Kidney International Reports, 2020

View PDFchevron_right